Amer Zeidan, Professor of Medicine, Chief of Hematologic Malignancies, Director of Heme Clinical Research at Yale University, shared a post on X:
”Another interesting abstract from EHA2026 that compared 6 prognostic tools for older unfit AML patients who received AZA-VEN and none of the models appeared better than the others, and all had modest performance in predicting survival. Interestingly, the 4-gene model which is the simplest and the first model to be introduced (and all subsequent models were introduced to improve upon it), had the best C-index, though again marginal.
206 patients were included, all treated with frontline non-IT within the CETLAM multicenter registry (mean age 75 years; 56% male), 103/199 (51.8%) were diagnosed with de novo AML and 71/197 (36%) had adverse risk karyotype (ELN2022). The majority of patients (190/206, 92%) received venetoclax-azacitidine. CR/CRi rate with venetoclax-azacitidine was 61.6%.
With a median follow-up of 11 months, median OS was 1.06 years (95% CI 0.89-1.42). All six models significantly stratified OS (Figure 1). Discriminatory performance was modest and largely overlapping, with the highest C-index observed for the 4-gene model (0.630), followed by PRISM (0.623), Beat-AML and refined ELN 2024 (0.612), molecular ontogeny (0.603) and Mayo (0.597).
Head-to-head comparison of six contemporary prognostic models in... – Rivero Equiza T – EHA-2983 – Jun 11 2026.”
Other Articles Featuring Amer Zeida on OncoDaily.